Companies / Japan
Takeda Poised For Acquisitions?
November 2006 | Industry NewsIn a possible change to its core growth strategy, leading Japanese drugmaker Takeda could be poised to make another large acquisition. The company - which has estimated cash reserves of more than US$14bn - has traditionally favoured intensive product development as its main engine for revenue growth. However, a weak R&D pipeline and slowness to embrace the potential of biotech may have prompted company officials to work on 'a number of deals' to expand inorganically. This could bolster the company's value while pipelines
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
